These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
620 related items for PubMed ID: 19435402
41. Pain management in palliative cancer patients: a prospective observational study on the use of high dosages of transdermal buprenorphine. Clement PM, Beuselinck B, Mertens PG, Cornelissen P, Menten J. Acta Clin Belg; 2013; 68(2):87-91. PubMed ID: 23967714 [Abstract] [Full Text] [Related]
42. [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)]. Leppert W, Luczak J, Gorzelińska L, Kozikowska J. Przegl Lek; 2000; 57(1):59-64. PubMed ID: 10907375 [Abstract] [Full Text] [Related]
43. Transdermal buprenorphine in children with cancer-related pain. Attinà G, Ruggiero A, Maurizi P, Arlotta A, Chiaretti A, Riccardi R. Pediatr Blood Cancer; 2009 Jan; 52(1):125-7. PubMed ID: 18802942 [Abstract] [Full Text] [Related]
44. [The transdermal 7-day buprenorphine patch--an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study]. Schutter U, Ritzdorf I, Heckes B. MMW Fortschr Med; 2010 Jul 01; 152 Suppl 2():62-9. PubMed ID: 21591321 [Abstract] [Full Text] [Related]
46. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Oifa S, Sydoruk T, White I, Ekstein MP, Marouani N, Chazan S, Skornick Y, Weinbroum AA. Clin Ther; 2009 Mar 01; 31(3):527-41. PubMed ID: 19393843 [Abstract] [Full Text] [Related]
47. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, Villari P, Ficorella C, Gebbia V, Riina S, Casuccio A, Mangione S. Eur J Pain; 2008 Nov 01; 12(8):1040-6. PubMed ID: 18353696 [Abstract] [Full Text] [Related]
49. Current knowledge of buprenorphine and its unique pharmacological profile. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, Mercadante S, Morlion B, Raffa RB, Sabatowski R, Sacerdote P, Torres LM, Weinbroum AA. Pain Pract; 2010 Nov 01; 10(5):428-50. PubMed ID: 20492579 [Abstract] [Full Text] [Related]
50. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S. J Pain Symptom Manage; 2009 Apr 01; 37(4):632-41. PubMed ID: 19345298 [Abstract] [Full Text] [Related]
51. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Koltzenburg M, Pokorny R, Gasser UE, Richarz U. Pain; 2006 Dec 15; 126(1-3):165-74. PubMed ID: 16901645 [Abstract] [Full Text] [Related]
52. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland. Przeklasa-Muszynska A, Dobrogowski J. Curr Med Res Opin; 2011 Jun 15; 27(6):1109-17. PubMed ID: 21456888 [Abstract] [Full Text] [Related]